{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T11:02:14Z","timestamp":1774263734334,"version":"3.50.1"},"reference-count":77,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.clml.2022.07.013","type":"journal-article","created":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T01:52:31Z","timestamp":1658541151000},"page":"795-804","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["SOHO State of the Art Updates and Next Questions | Mechanisms of Resistance to BCL2 Inhibitor Therapy in Chronic Lymphocytic Leukemia and Potential Future Therapeutic Directions"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4037-4536","authenticated-orcid":false,"given":"Rory","family":"Bennett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ella","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantine","family":"Tam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.07.013_bib0001","first-page":"456","article-title":"Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome","volume":"10","author":"Robertson","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.07.013_bib0002","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1182\/blood-2007-07-098681","article-title":"BCL2 expression in chronic lymphocytic leukemia: lack of association with the BCL2 \u2212938A>C promoter single nucleotide polymorphism","volume":"111","author":"Majid","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.013_bib0003","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/cdd.2017.186","article-title":"BCL-2 family proteins: changing partners in the dance towards death","volume":"25","author":"Kale","year":"2018","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.clml.2022.07.013_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hematology.2020000154","article-title":"Therapeutic development and current uses of BCL-2 inhibition","volume":"2020","author":"Roberts","year":"2020","journal-title":"Hematology"},{"key":"10.1016\/j.clml.2022.07.013_bib0005","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrm2308","article-title":"The BCL-2 protein family: opposing activities that mediate cell death","volume":"9","author":"Youle","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.clml.2022.07.013_bib0006","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"Wilson","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.07.013_bib0007","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.013_bib0008","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.07.013_bib0009","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase i first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.013_bib0010","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","article-title":"Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1B study","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.07.013_bib0011","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/blood.2018882555","article-title":"Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables","volume":"134","author":"Roberts","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.013_bib0012","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax\u2013rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.07.013_bib0013","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.07.013_bib0014","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.07.013_bib0015","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1200\/JCO.21.00807","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II captivate study","volume":"39","author":"Wierda","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.013_bib0016","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/cdd.2017.159","article-title":"BCL2 and miR-15\/16: from gene discovery to treatment","volume":"25","author":"Pekarsky","year":"2018","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.clml.2022.07.013_bib0017","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1182\/blood-2013-10-534073","article-title":"Stimulation of the B-cell receptor activates the JAK2\/STAT3 signaling pathway in chronic lymphocytic leukemia cells","volume":"123","author":"Rozovski","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.013_bib0018","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa050995","article-title":"A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia","volume":"353","author":"Calin","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.07.013_bib0019","first-page":"2628","article-title":"Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed\/refractory follicular lymphoma","volume":"136","author":"Zinzani","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.013_bib0020","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3389\/fonc.2018.00636","article-title":"Targeting the Bcl-2 Family in B Cell Lymphoma","volume":"8","author":"Adams","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2022.07.013_bib0021","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1182\/blood-2011-03-340364","article-title":"An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737","volume":"118","author":"Al-harbi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.013_bib0022","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/bph.13370","article-title":"Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding","volume":"173","author":"Song","year":"2016","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clml.2022.07.013_bib0023","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1515\/hsz-2016-0107","article-title":"iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry","volume":"397","author":"Ryan","year":"2016","journal-title":"Biol Chem"},{"key":"10.1016\/j.clml.2022.07.013_bib0024","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","article-title":"Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies","volume":"36","author":"Gui\u00e8ze","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2022.07.013_bib0025","doi-asserted-by":"crossref","unstructured":"Burger JA, Gribben JG. The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: Insight into disease biology and new targeted therapies. Microenviron Lymphomas. 2014;24:71-81. doi:10.1016\/j.semcancer.2013.08.011","DOI":"10.1016\/j.semcancer.2013.08.011"},{"key":"10.1016\/j.clml.2022.07.013_bib0026","first-page":"e302","article-title":"Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors","volume":"100","author":"Thijssen","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.07.013_bib0027","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/bloodadvances.2016004176","article-title":"Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL","volume":"1","author":"Jayappa","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.07.013_bib0028","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood.2019004326","article-title":"Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL","volume":"136","author":"Haselager","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.013_bib0029","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1182\/bloodadvances.2019000367","article-title":"Clonal dynamics in chronic lymphocytic leukemia","volume":"3","author":"Gutierrez","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.07.013_bib0030","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature15395","article-title":"Mutations driving CLL and their evolution in progression and relapse","volume":"526","author":"Landau","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.clml.2022.07.013_bib0031","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1182\/blood.2019004492","article-title":"Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax","volume":"135","author":"Tausch","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.013_bib0032","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood-2017-01-763003","article-title":"Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax","volume":"129","author":"Anderson","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.013_bib0033","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.777587","article-title":"Notch2 increases the resistance to venetoclax-induced apoptosis in chronic lymphocytic leukemia B cells by inducing MCL-1","volume":"11","author":"Fiorcari","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.clml.2022.07.013_bib0034","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","article-title":"Dynamic molecular monitoring reveals that SWI\u2013SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma","volume":"25","author":"Agarwal","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2022.07.013_bib0035","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1182\/blood-2015-02-585042","article-title":"Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia","volume":"126","author":"Gui\u00e8ze","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.013_bib0036","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41586-019-1198-z","article-title":"Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia","volume":"569","author":"Gaiti","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.clml.2022.07.013_bib0037","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the recurrent GLY101VAL mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2022.07.013_bib0038","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.3324\/haematol.2019.222588","article-title":"Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia","volume":"104","author":"Tausch","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.07.013_bib0039","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1038\/s41467-019-10363-1","article-title":"Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations","volume":"10","author":"Birkinshaw","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2022.07.013_bib0040","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1182\/blood.2019004205","article-title":"Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax","volume":"135","author":"Blombery","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.013_bib0041","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1182\/blood.2019003722","article-title":"Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK\/PLCG2 mutations","volume":"135","author":"Lucas","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.013_bib0042","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2022.07.013_bib0043","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1182\/blood-2014-03-560284","article-title":"Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma","volume":"123","author":"Fresquet","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.013_bib0044","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1182\/blood-2006-05-021683","article-title":"Differential Noxa\/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity","volume":"109","author":"Smit","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.013_bib0045","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41419-020-03144-y","article-title":"Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance","volume":"11","author":"Kapoor","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.clml.2022.07.013_bib0046","doi-asserted-by":"crossref","first-page":"70000","DOI":"10.18632\/oncotarget.12132","article-title":"Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells","volume":"7","author":"Bodo","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2022.07.013_bib0047","doi-asserted-by":"crossref","first-page":"e1593","DOI":"10.1038\/cddis.2014.525","article-title":"MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies","volume":"6","author":"Choudhary","year":"2015","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.clml.2022.07.013_bib0048","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1186\/s12885-017-3383-5","article-title":"Potential mechanisms of resistance to venetoclax and strategies to circumvent it","volume":"17","author":"Tahir","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2022.07.013_bib0049","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/s41418-020-00692-w","article-title":"Regulation of Bcl-XL by non-canonical NF-\u03baB in the context of CD40-induced drug resistance in CLL","volume":"28","author":"Haselager","year":"2021","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.clml.2022.07.013_bib0050","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1038\/onc.2010.248","article-title":"Dichotomy in NF-\u03baB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40\/TLR9 triggering","volume":"29","author":"Tromp","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2022.07.013_bib0051","first-page":"40","article-title":"NF-\u03baB activation in chronic lymphocytic leukemia: a point of convergence of external triggers and intrinsic lesions","volume":"39","author":"Mansouri","year":"2016","journal-title":"B-Cell Malig \u2013 Roads Lead NF-\u039aB Act"},{"key":"10.1016\/j.clml.2022.07.013_bib0052","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1158\/1078-0432.CCR-12-3151","article-title":"NIK controls classical and alternative NF-\u03baB activation and is necessary for the survival of human T-cell lymphoma cells","volume":"19","author":"Odqvist","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2022.07.013_bib0053","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1083\/jcb.200708096","article-title":"A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation","volume":"180","author":"Lee","year":"2008","journal-title":"J Cell Biol"},{"key":"10.1016\/j.clml.2022.07.013_bib0054","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1111\/febs.14505","article-title":"Phosphorylation alters bim-mediated Mcl-1 stabilization and priming","volume":"285","author":"Conage-Pough","year":"2018","journal-title":"FEBS J"},{"key":"10.1016\/j.clml.2022.07.013_bib0055","doi-asserted-by":"crossref","first-page":"16912","DOI":"10.18632\/oncotarget.4857","article-title":"Cyclin E\/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics","volume":"6","author":"Choudhary","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2022.07.013_bib0056","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1038\/onc.2016.515","article-title":"Macrophages confer survival signals via CCR1-dependent translational MCL-1 induction in chronic lymphocytic leukemia","volume":"36","author":"van Attekum","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2022.07.013_bib0057","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1182\/bloodadvances.2019000844","article-title":"Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models","volume":"4","author":"Tarantelli","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.07.013_bib0058","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1182\/blood-2018-08-872465","article-title":"Targeted inhibition of PI3K\u03b1\/\u03b4 is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL","volume":"133","author":"Bojarczuk","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.013_bib0059","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1038\/leu.2016.382","article-title":"Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199)","volume":"31","author":"Patel","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.07.013_bib0060","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1158\/0008-5472.CAN-11-4106","article-title":"Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells","volume":"72","author":"Mazumder","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2022.07.013_bib0061","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1182\/blood-2005-04-1678","article-title":"Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death","volume":"106","author":"Chen","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.013_bib0062","first-page":"15","article-title":"High clonal complexity of resistance mechanisms occurring at progression after single-agent targeted therapy strategies in chronic lymphocytic leukemia","volume":"136","author":"Thompson","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.013_bib0063","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/bloodadvances.2021006211","article-title":"Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors","volume":"6","author":"Thompson","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.07.013_bib0064","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1182\/blood.2021012775","article-title":"Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL","volume":"139","author":"Blombery","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.013_bib0065","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2020-137775","article-title":"BAX-mutated clonal hematopoiesis in patients on long-term venetoclax for relapsed\/refractory chronic lymphocytic leukemia","volume":"136","author":"Blombery","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.013_bib0066","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1074\/jbc.RA119.011635","article-title":"Mitochondrial residence of the apoptosis inducer BAX is more important than BAX oligomerization in promoting membrane permeabilization","volume":"295","author":"Kuwana","year":"2020","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clml.2022.07.013_bib0067","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1182\/blood-2019-127458","article-title":"Identification of recurrent genomic alterations in the apoptotic machinery in CLL patients treated with venetoclax monotherapy","volume":"134","author":"Chyla","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.013_bib0068","doi-asserted-by":"crossref","first-page":"E47","DOI":"10.1002\/ajh.26411","article-title":"Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy","volume":"97","author":"Popovic","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.07.013_bib0069","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41467-018-03170-7","article-title":"Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia","volume":"9","author":"Herling","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2022.07.013_bib0070","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.20.00948","article-title":"Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study","volume":"38","author":"Kater","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.013_bib0071","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1200\/JCO.18.01580","article-title":"Fixed duration of venetoclax-rituximab in relapsed\/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase iii study","volume":"37","author":"Kater","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2022.07.013_bib0072","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3390\/jpm11060463","article-title":"Review of venetoclax in CLL, AML and multiple myeloma","volume":"11","author":"Lasica","year":"2021","journal-title":"J. Pers. Med"},{"key":"10.1016\/j.clml.2022.07.013_bib0073","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.19.00894","article-title":"Ibrutinib plus venetoclax in relapsed\/refractory chronic lymphocytic leukemia: the CLARITY study","volume":"37","author":"Hillmen","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.013_bib0074","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","article-title":"Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"11","author":"Pullarkat","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2022.07.013_bib0075","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13045-021-01079-1","article-title":"Targeting MCL-1 in cancer: current status and perspectives","volume":"14","author":"Wang","year":"2021","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"10.1016\/j.clml.2022.07.013_bib0076","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1200\/JCO.2017.76.6840","article-title":"Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial","volume":"36","author":"Stilgenbauer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.013_bib0077","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022002336?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022002336?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:40:43Z","timestamp":1761871243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022002336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":77,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S2152265022002336"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.07.013","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Mechanisms of Resistance to BCL2 Inhibitor Therapy in Chronic Lymphocytic Leukemia and Potential Future Therapeutic Directions","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}